Efficacy and safety of a lower-dose valganciclovir (Valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients

P and T

Volumn 35, Issue 12, 2010, Pages 676-679

  Bhat, Vrinda ^a   McIntyre, Megan ^a   Meyers, Tracey ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PANCREAS TRANSPLANTATION; PROPHYLAXIS;

EID: 78650208548     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Cytomegalovirus. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004;4(Suppl. 10):51-58.
2. Chamberlain CE, Penzak SR, Alfaro RM, et al. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008;8:1297-1302. (Pubitemid 351763675)
3. Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc 2008;40:752-754. (Pubitemid 351608651)
4. Weng FL, Patel AM, Wanchoo R, et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007;83(3):290-296.
5. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6(2):262-274.
6. Akalin E, Bromberg JS, Sehgal V, et al. Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 2004;4:148-149. (Pubitemid 38155504)
7. Luan FL, Stuckey LJ, Park JM, et al. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009;20:2449-2458.
8. Gabardi S, Magee CC, Baroletti SA, et al. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis. Pharmacotherapy 2004;24:1323-1330.